🟢 Precision Oncology through Biomarkers: Assessing What Matters Most — Renal Stefanie Zschäbitz at #IUCS26 🟢 ctDNA is emerging as a powerful prognostic tool in RCC, but its role still depends strongly on disease setting, assay sensitivity and timing. 🟢 In the perioperative setting, tumor-informed ctDNA may help identify patients at higher risk of recurrence, while serial pre- and post-surgical assessment appears more informative than a single time point. 🟢 In KEYNOTE-564, ctDNA positivity identified a subgroup with markedly poorer disease-free survival — reinforcing the potential of molecular residual disease as a future risk-stratification tool. 🟢 KIM-1 is another promising biomarker in RCC: a transmembrane glycoprotein overexpressed in clear-cell and papillary RCC, measurable both in tissue and serum, with growing interest in prognosis and treatment monitoring. 🟢 PD-L1 alone remains insufficient as a treatment-selection biomarker in mRCC. Across contemporary immune-based combinations, benefit cannot be reliably reduced to PD-L1 status alone. 🟢 Ongoing strategies such as CARE-1 are testing whether biomarker-defined populations can better guide the choice between dual immunotherapy and immunotherapy + anti-angiogenic therapy. 🟢 Belzutifan illustrates precision oncology beyond conventional biomarkers, with established activity in VHL-driven disease and growing real-world and trial evidence across RCC settings. 🟢 Emerging targets are expanding the renal cancer biomarker landscape: • FAP as a marker of aggressive biology and potential imaging target • Carbonic anhydrase IX for theranostic approaches • ROR2, CAIX and CD70 as potential cellular-therapy targets 🟢 The take-home message: precision oncology in RCC is moving from static single biomarkers toward dynamic, multimodal assessment — tissue, ctDNA, serum markers, imaging and tumor biology — used at the right time for the right clinical question. @neerajaiims @gbanna74 @Sebastiano_Buti @CinziaConted @dralishadamani @nataliagandur @amg120395 @PGrivasMDPhD @ravikanesvaran @koshkin85 @MicheleMaffezz @ManiamAkash @ParamMariappan @dmukherji @VanitaNoronha @montypal @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @DrYukselUrun @yekeduz_emre @myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb #KidneyCancer #RCC #GUOncology #PrecisionOncology #Biomarkers